About
Copy Link
Titles
Instructor
Biography
Krupa Jani, MD, PhD, is an instructor of clinical therapeutic radiology. Dr. Jani completed her residency training at Yale, where she served as a chief resident 2025-2026. Her clinical practice will focus on breast, genitourinary, head and neck, and CNS malignancies, while her research interests are focused on understanding chromatin and epigenetics in the context of cancer and cancer therapies.
Hometown: Rockaway, NJ.
Research Interests: Epigenetics, chromatin modifying enzymes, chromatin structure and repair, radiosensitizers.
Last Updated on July 27, 2026.
Appointments
Therapeutic Radiology
InstructorPrimary
Other Departments & Organizations
Education & Training
- Residency - Radiation Oncology
- Yale School of Medicine (2026)
- Internship - General Surgery
- Robert Wood Johnson Medical School/Rutgers University (2022)
- MD
- Rutgers University Robert Wood Johnson Medical School (2021)
- PhD
- Princeton University, Molecular Biology (2019)
- BS
- The College of New Jersey, Biology (2011)
Research
Copy Link
Overview
Dr. Jani conducts research on understanding the role of epigenetics in cancer progression, particularly in the context of DNA and chromatin damage and repair.
ORCID
0000-0002-3103-4575
Research at a Glance
Publications Timeline
A big-picture view of Krupa Jani's research output by year.
9Publications
591Citations
Publications
2021
Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis
Jani K, Lu S, Murphy J, Romesser P, Jethwa K, Li D, Chundury A, Wu A, Hathout L, Hallemeier C, Jabbour S. Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis. Cancer Medicine 2021, 10: 3575-3583. PMID: 33960690, PMCID: PMC8178496, DOI: 10.1002/cam4.3909.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnus NeoplasmsCarcinoma, Squamous CellColonic NeoplasmsFemaleGastrointestinal NeoplasmsHumansIncidenceLung NeoplasmsLymphomaLymphoma, Non-HodgkinMaleMelanomaNeoplasms, Second PrimaryOropharyngeal NeoplasmsProstatic NeoplasmsRiskSarcoma, KaposiSEER ProgramSkin NeoplasmsUnited StatesVulvar NeoplasmsConceptsAnal squamous cell carcinomaUS population-based studyStandardized incidence ratioSquamous cell carcinomaCell carcinomaPrimary anal squamous cell carcinomaRadiation treatmentRisk of SPMElevated incidenceIncidence of SPMsDiagnosis of cancerSingle-institution studyStudy of patientsIncidence ratiosRegistry dataCancer diagnosisVulvar cancerPrimary malignancyGeneral populationProstate cancerKaposi's sarcomaEnd ResultsFemale genital systemMalignancyRegistry analysis
2020
Increased Incidence of Malignancy Before and after Chemoradiation for Anal Squamous Cell Carcinoma: A Multi-Institutional Analysis
Jabbour S, Hallemeier C, Chang D, Lu S, Hristidis V, Jethwa K, Baclay J, Li D, Chakrani Z, Haddock M, Toesca D, Jani K, Wu A, Sandhyavenu H, Minneci M, Romesser P. Increased Incidence of Malignancy Before and after Chemoradiation for Anal Squamous Cell Carcinoma: A Multi-Institutional Analysis. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e597-e598. DOI: 10.1016/j.ijrobp.2020.07.1824.Peer-Reviewed Original ResearchThe Evolving Role of Radiotherapy in Locally Advanced Rectal Cancer and the Potential for Nonoperative Management
Khullar K, Patel N, Anderson C, Chundury A, Carpizo D, Feingold D, Grandhi M, Hochster H, Jani K, Kennedy T, Langan R, Spencer K, August D, Jabbour S, Department of Radiation Oncology R, Department of Surgery R, Division of Surgical Oncology R, Division of Medical Oncology R. The Evolving Role of Radiotherapy in Locally Advanced Rectal Cancer and the Potential for Nonoperative Management. TouchREVIEWS In Oncology & Haematology 2020, 16: 43. PMID: 32832093, PMCID: PMC7439775, DOI: 10.17925/ohr.2020.16.1.43.Peer-Reviewed Original ResearchCitationsConceptsLocally Advanced Rectal CancerAdvanced rectal cancerRectal cancerNonoperative managementLymph node-positive diseaseRate of sphincter preservationShort-course radiationNode-positive diseaseLong-course chemoradiationRectal Cancer TrialRates of toxicityStandard of careEvolution of treatmentMagnetic resonance imagingAdjuvant chemoradiationNeoadjuvant chemoradiationNeoadjuvant treatmentLocal recurrencePostoperative chemoradiationSphincter preservationRisk stratificationChemoradiationProspective dataOptimal managementCancer trials
2019
PRC2 engages a bivalent H3K27M-H3K27me3 dinucleosome inhibitor
Diehl K, Ge E, Weinberg D, Jani K, Allis C, Muir T. PRC2 engages a bivalent H3K27M-H3K27me3 dinucleosome inhibitor. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 22152-22157. PMID: 31611394, PMCID: PMC6825254, DOI: 10.1073/pnas.1911775116.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsNucleation and Propagation of Heterochromatin by the Histone Methyltransferase PRC2: Geometric Constraints and Impact of the Regulatory Subunit JARID2
Ge E, Jani K, Diehl K, Müller M, Muir T. Nucleation and Propagation of Heterochromatin by the Histone Methyltransferase PRC2: Geometric Constraints and Impact of the Regulatory Subunit JARID2. Journal Of The American Chemical Society 2019, 141: 15029-15039. PMID: 31479253, PMCID: PMC6941475, DOI: 10.1021/jacs.9b02321.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPolycomb repressive complex 2Polycomb repressive complex 2 activityPRC2 core complexH3K27 methylationMaintenance of cell identitySubunit of polycomb repressive complex 2Propagation of heterochromatinH3K27 methylation marksTrimethylation of lysineExpression of genesChromatin substratesChromatin modificationsMethylation marksPositive feedback loopCell identityHistone H3Allosteric activationBiochemical insightsCondensed heterochromatinJARID2HeterochromatinChromatinCore complexHistoneAncillary subunitsHistone H3 tail binds a unique sensing pocket in EZH2 to activate the PRC2 methyltransferase
Jani K, Jain S, Ge E, Diehl K, Lundgren S, Müller M, Lewis P, Muir T. Histone H3 tail binds a unique sensing pocket in EZH2 to activate the PRC2 methyltransferase. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 8295-8300. PMID: 30967505, PMCID: PMC6486736, DOI: 10.1073/pnas.1819029116.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPolycomb repressor complex 2Catalytic subunitCatalytic subunit of Polycomb Repressor Complex 2Associated with transcriptional silencingEnzymatic activityHistone H3 tailH3K36 methylation statesMethyltransferase activity assaysTrimethylation of lysineCases of Weaver syndromeH3K36 methylationH3 tailNucleosome substratesH3K36 trimethylationTranscriptional silencingMethylation stateMethylation patternsHistone tailsH3K27 methylationH3K36Histone H3Molecular detailsTranscriptional profilesHistoneH3K27
2016
Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape
Lu C, Jain SU, Hoelper D, Bechet D, Molden RC, Ran L, Murphy D, Venneti S, Hameed M, Pawel BR, Wunder JS, Dickson BC, Lundgren SM, Jani KS, De Jay N, Papillon-Cavanagh S, Andrulis IL, Sawyer SL, Grynspan D, Turcotte RE, Nadaf J, Fahiminiyah S, Muir TW, Majewski J, Thompson CB, Chi P, Garcia BA, Allis CD, Jabado N, Lewis PW. Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. Science 2016, 352: 844-849. PMID: 27174990, PMCID: PMC4928577, DOI: 10.1126/science.aac7272.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsH3K36 methylationH3K36 methyltransferasesPolycomb Repressive Complex 1Repressive Complex 1H3 lysine 36Mesenchymal progenitor cellsMutant nucleosomesMethylation landscapeLysine 36H3K27 methylationHistone H3Target genesMethionine mutationMissense mutationsMethylationOncogenic mechanismsProgenitor cellsEnzymatic activityMethyltransferasesMutationsMesenchymal differentiationDifferentiationH3.1NucleosomesM mutation
2012
Computational Design of Targeted Inhibitors of Polo-Like Kinase 1 (Plk1)
Jani K, Dalafave D. Computational Design of Targeted Inhibitors of Polo-Like Kinase 1 (Plk1). Bioinformatics And Biology Insights 2012, 6: bbi.s8971. PMID: 22399850, PMCID: PMC3290105, DOI: 10.4137/bbi.s8971.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPolo-box domainDocking studiesOne-moleculeStable complexesPlk1-specific inhibitorsDrug likenessComputational designSmall moleculesDown-regulation of Plk1MoleculesStructural featuresATP-binding siteATP siteInhibitor of polo-like kinase 1LigandDockingPolo-boxPutative inhibitorPolo-like kinase 1Likely values
2011
Computational Design of Small Molecules with Druglike Properties
Dalafave D, Jani K. Computational Design of Small Molecules with Druglike Properties. Biophysical Journal 2011, 100: 216a. DOI: 10.1016/j.bpj.2010.12.1393.Peer-Reviewed Original Research
Clinical Care
Copy Link
Overview
Clinical Specialties
Therapeutic Radiology
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileGet In Touch
Copy Link
Contacts
Email
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.